News about Eyenovia Inc

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
Mar 20 2025
Eyenovia Inc. Enters Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq: A New Era in Eye CareIn a groundbreaking move that could res...

Eyenovia Strives for Compliance Amid Market Headwinds: A 1-for-80 Reverse Stock Split
Jan 28 2025
Eyenovia Inc. a biopharmaceutical firm specialized in ophthalmic therapeutics, recently announced a decisive move to implement a 1-for-80 reverse stoc...

Eyenovia, Inc. Prepares for Crucial Virtual Stockholder Meeting Following Significant Share Price Decline Amid Recent Funding Initiatives
Jan 15 2025
Eyenovia, Inc. (NASDAQ: EYEN), a pioneer in ophthalmic technology, is positioning itself for a critical interaction with its shareholders through an i...

Eyenovia, Inc. Strives for Resilience: Navigating Financial Opportunities Amid Clinical Setbacks,
Nov 25 2024
Eyenovia, Inc. Secures $1.3 Million in Share Offering Amidst Challenges in Ocular TherapeuticsBy , NEW YORK, Nov. 25, 2024 Eyenovia, Inc., a pioneer...

Eyenovias CHAPERONE Study A Setback in Ocular Therapeutics as Efficacy Endpoint Remains Unmet
Nov 15 2024
Eyenovia Provides Update on Phase 3 CHAPERONE Study: A Critical Review of Data and Outcomes Eyenovia, a clinical-stage biopharmaceutical company speci...

Eyenovias Gen-2 Optejet A Visionary Leap Towards Next-Gen Ophthalmic Care,
Oct 01 2024
Revolutionizing Eye Care: Eyenovia s Gen-2 Optejet Marks a New Era in Ophthalmic Drug Delivery In the fast-evolving sphere of ophthalmic care, Eyenovi...

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
Sep 27 2024
Eyenovia, Inc. Strengthens Financial Position and Product Pipeline with $4 Million Registered Direct OfferingEyenovia, Inc. (NASDAQ: EYEN), an innovat...

Eyenovia Inc. Launches Clobetasol Propionate Ophthalmic Suspension A New Option for Post-Operative Management in Opht...
Sep 26 2024
In an exciting development within the ophthalmic pharmaceutical landscape, Eyenovia Inc. has announced the launch and commercial availability of Clobe...

Eyenovia Advances Ophthalmic Product Pipeline with Upcoming U.S. Launch and Manufacturing Expansion
Sep 05 2024
Eyenovia, Inc., a clinical-stage biotech company specializing in ophthalmic therapeutics, has made significant strides in its product lineup, recently...

nnEyenovia Secures $5.14 Million Fundraising Through $0.40 Per Share Public Offering Despite Recent $32 Million Net Loss,
Aug 21 2024
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, recently unveiled plans for a public offering, agreeing to sell 12,850,000 ...

Eyenovia Inc Reports Revenue of $0.004993 Million in Q1 2024 Financial Update
May 16 2024
Eyenovia Inc, a clinical stage ophthalmic company, recently provided updates on its FDA-approved products and expansion plans. The company disclosed i...

Eyenovia Inc Faces Challenges as Shares Plummet and Future Prospects Remain Uncertain
Mar 19 2024
Eyenovia Inc, a major pharmaceutical preparations company, has witnessed a significant drop in its shares over the past month. This decline ...

Eyenovia Inc Reveals Promising Q3 2023 Financial Report with Revenue of $1.2 Million
Nov 14 2023
As the third quarter of the 2023 earnings season comes to a close, Eyenovia Inc ? a leading biopharmaceutical company specializing in innova...

SUBTITLE: Eyenovia Inc battles financial challenges while striving to revolutionize eye disease treatments
May 14 2023
Eyenovia Inc is a healthcare company that mainly focuses on developing and commercializing topical medications for the treatment of eye diseases and c...